CDX2 and gastric adenocarcinoma: However, there is evidence that CDX2 is positive in subgroups of ovarian mucinous adenocarcinomas; 30% of cervical mucinous adenocarcinomas [33]; small intestine carcinoma; 36–70% of gastric adenocarcinomas, including signet ring cell adenocarcinomas, urothelial carcinoma, and pancreatic [34], ileal, and appendicular neuroendocrine tumors.